Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Sanofi posts higher earnings and sales, sees further growth ahead
01:46am, Thursday, 28'th Apr 2022
Sanofi SA on Thursday posted higher earnings and sales for the first quarter, driven by best-selling drug Dupixent and consumer healthcare, and said that it expects further growth in business earnings
Sanofi operating income up 16% on bestseller drug Dupixent
01:38am, Thursday, 28'th Apr 2022
French healthcare group Sanofi's first quarter adjusted earnings gained 16.2% on continued sales growth of its bestselling drug Dupixent.
Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More
06:03pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.
Bristol-Myers (BMY) to Post Q1 Earnings: Is a Beat in Store?
04:00pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Bristol-Myers (BMY) Q1 earnings might have gained from strong demand for Eliquis and incremental contribution from newer drugs. Operating expenses might have jumped on broader portfolio-related costs.
Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More
03:18pm, Wednesday, 27'th Apr 2022
Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.
Should You Buy Sanofi (SNY) Ahead of Earnings?
12:42pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Exscientia: Drug Discovery Using AI For Sanofi And Self-Owned Pipeline
02:05am, Tuesday, 12'th Apr 2022
Exscientia: Drug Discovery Using AI For Sanofi And Self-Owned Pipeline
Could This Drug Candidate Be a Blockbuster for Sanofi?
11:45am, Saturday, 09'th Apr 2022
The pharma giant recently shared encouraging results from a late-stage clinical trial for its hemophilia drug candidate.
Regeneron (REGN), Sanofi's Dupixent Gets EU Nod for Asthma in Kids
04:34pm, Thursday, 07'th Apr 2022
Regeneron (REGN) and Sanofi's (SNY) Dupixent receives label expansion in the European Union for severe asthma with type 2 inflammation in children aged between 6 years and 11 years.
Sanofi (SNY) Stock Outperforms Industry YTD: What Lies Ahead?
09:47am, Thursday, 07'th Apr 2022
Here we discuss some factors that have been driving Sanofi's (SNY) stock and its outlook for the future.
Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA
12:03pm, Monday, 04'th Apr 2022
The FDA accepts and grants priority review to Regeneron (REGN) and Sanofi's sBLA for Dupixent to treat eosinophilic esophagitis in patients aged 12 years and older. A decision is due on Aug 3, 2022.
Sanofi to list drug ingredients business on May 6
02:19am, Friday, 01'st Apr 2022
Sanofi expects to list its drug ingredients business EUROAPI on May 6, having received approval from French stock market regulator, the pharmaceutical giant said on Friday.
Regeneron, IGM Biosciences Shares Up Big on Sanofi Deals
04:52pm, Thursday, 31'st Mar 2022
A week filled with promising announcements failed to jump-start Sanofi SA's ( SNY , Financial) shares, but it did for the two companies it's working with.
France's Sanofi offers 1.5 billion euro bond linked to access to medicine
01:28am, Thursday, 31'st Mar 2022
French healthcare group Sanofi said it had priced a first sustainability-linked bond issue that will be indexed on access to medicines, and worth 1.5 billion euros ($1.7 billion).
IGM (IGMS) Skyrockets on Collaboration Deal With Sanofi
01:33pm, Wednesday, 30'th Mar 2022
IGM Biosciences (IGMS) inks a deal with Sanofi (SNY) to discover and develop new therapies based on its proprietary technology, which is set to target oncology, immunology and inflammation targets.
